Does KPV act on melanocortin receptors?

That is not the primary route described. At 342 Da it is small enough for an intracellular mechanism its 1,665 Da parent hormone could not have.

A transcription factor central to inflammatory signalling, driving cytokine production when activated. Interfering with it affects many downstream outputs at once.

Is there human evidence?

No established clinical programme. The literature is cell culture and murine models.

KPV

How KPV Is Reported to Act

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Reported activity centres on interference with NF-κB signalling and reduced pro-inflammatory cytokine production. Unlike its parent hormone, KPV's described action is not primarily receptor-mediated — it is small enough to enter cells, which changes what kind of mechanism is plausible.

Key facts

Reported target: NF-κB signalling
Reported effect: Reduced pro-inflammatory cytokines
Melanocortin receptor: Not the primary route described
Size advantage: 342 Da — small enough to enter cells
Model systems: Cell culture and murine models
Human clinical data: None established

What NF-κB does

NF-κB is a transcription factor and one of the central switches of inflammatory signalling. Held inactive in the cytoplasm under normal conditions, it moves to the nucleus when inflammatory signals arrive and drives transcription of cytokines and other inflammatory mediators. Interfering with it affects a broad set of downstream outputs at once.

Why size changes the mechanism question

Alpha-MSH at 1,665 Da acts at cell-surface melanocortin receptors — it is far too large to cross a membrane passively. KPV at 342 Da is a different proposition entirely. A tripeptide of that size can plausibly enter cells, which permits an intracellular mechanism the parent hormone could not have. That is the most interesting structural consequence of the fragment being so short.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

What the models measured

Kannengiesser and colleagues reported anti-inflammatory potential in murine colitis models in 2008. Cell-culture work has examined cytokine production and NF-κB pathway activity. These establish that the compound does something measurable to inflammatory signalling in those systems — which is a statement about those systems.

Why the delivery paper is informative

Xiao and colleagues published on orally targeted delivery of KPV using hyaluronic acid-functionalised nanoparticles in Molecular Therapy in 2017. Researchers do not build targeted delivery systems for compounds that reach their target unaided. The existence of that work tells you the free tripeptide's own delivery to inflamed tissue was the limiting problem.

What is not established

A defined molecular target. NF-κB interference is a described effect rather than a mapped binding interaction, and no receptor or direct binding partner has been characterised. As with several compounds in this library, the downstream consequences are better documented than the initiating event.

And what is not claimed

Nothing about inflammation in people. The work is cell culture and murine models, there is no established human clinical programme, and KPV holds no marketing authorisation anywhere. Colitis models are disease models, not evidence of a treatment.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does KPV act on melanocortin receptors?: That is not the primary route described. At 342 Da it is small enough for an intracellular mechanism its 1,665 Da parent hormone could not have.
What is NF-κB?: A transcription factor central to inflammatory signalling, driving cytokine production when activated. Interfering with it affects many downstream outputs at once.
Is there human evidence?: No established clinical programme. The literature is cell culture and murine models.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum